Survodutide

Grade B: Human evidence, not approved for this use

TL;DR: Survodutide is an investigational once-weekly injectable dual agonist of the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim for obesity and metabolic-associated steatohepatitis (MASH). In a Phase 2 RCT published in NEJM (2024), survodutide demonstrated significant MASH resolution (83% without fibrosis worsening at the 4.8 mg dose vs. 18% placebo) alongside meaningful weight loss. In Phase 3, the SYNCHRONIZE-1 trial (obesity without T2D) reported approximately 16.6% mean weight loss over 76 weeks versus approximately 3.2% with placebo; separately, the SYNCHRONIZE-NAFLD trial (liver disease population) reported 62.9% NASH resolution without fibrosis worsening at 48 weeks. These are distinct trials: SYNCHRONIZE-1 evaluated obesity as the primary endpoint; SYNCHRONIZE-NAFLD evaluated liver histology in a liver disease population. Boehringer Ingelheim submitted an NDA to FDA in early 2026; FDA review is ongoing and approval had not occurred as of June 2026. Evidence is Grade B given Phase 3 completion but no regulatory approval yet.

Key Takeaways

Grade B: Human evidence, not approved for this use
Not FDA approved: Investigational; NDA submitted to FDA in early 2026, regulatory review ongoing as of June 2026.
Compounding: Not approved by FDA as of June 2026. NDA under FDA review. Survodutide is not eligible for compounding under 503A or 503B; compounding of unapproved drug substances requires FDA authorization not currently in place for this agent.

Survodutide chemical structure — Structure via PubChem CID 171378821

Mechanism

Dual agonism at GLP-1 and glucagon receptors suppresses appetite and enhances satiety via GLP-1 signaling while increasing hepatic fat oxidation and energy expenditure via glucagon receptor activation.

Evidence

Survodutide is an investigational once-weekly injectable dual agonist of the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim for obesity and metabolic-associated steatohepatitis (MASH). In a Phase 2 RCT published in NEJM (2024), survodutide demonstrated significant MASH resolution (83% without fibrosis worsening at the 4.8 mg dose vs. 18% placebo) alongside meaningful weight loss. In Phase 3, the SYNCHRONIZE-1 trial (obesity without T2D) reported approximately 16.6% mean weight loss over 76 weeks versus approximately 3.2% with placebo; separately, the SYNCHRONIZE-NAFLD trial (liver disease population) reported 62.9% NASH resolution without fibrosis worsening at 48 weeks. These are distinct trials: SYNCHRONIZE-1 evaluated obesity as the primary endpoint; SYNCHRONIZE-NAFLD evaluated liver histology in a liver disease population. Boehringer Ingelheim submitted an NDA to FDA in early 2026; FDA review is ongoing and approval had not occurred as of June 2026. Evidence is Grade B given Phase 3 completion but no regulatory approval yet.

Safety and risks

Gastrointestinal adverse events were high-burden in Phase 2 MASH trial data: nausea occurred in approximately 66% of survodutide-treated patients versus 23% with placebo; diarrhea in approximately 49% versus 23%; and vomiting in approximately 41% versus 4%. Discontinuation due to adverse events occurred in approximately 20% of survodutide-treated participants versus 3% on placebo in the MASH Phase 2 trial, with the majority occurring during the aggressive rapid-dose-escalation phase. Because survodutide contains a GLP-1 receptor agonist component, it carries the class risk of thyroid C-cell tumors observed in rodent studies; patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) were excluded from trials and should not use GLP-1-containing agents. The glucagon receptor component introduces distinct hepatic metabolic effects (increased hepatic glucose output, effects on lipid metabolism) that require monitoring, separate from pure GLP-1 agents. Standard GLP-1 class precautions also apply: acute pancreatitis, gallbladder disease, volume depletion-related acute kidney injury, and pulmonary aspiration risk during anesthesia. The full risk profile in Phase 3 populations remains to be characterized in regulatory review.

Interactions

No approved label; class-level GLP-1 interactions anticipated including enhanced hypoglycemia with insulin or secretagogues; glucagon receptor activity may influence hepatic glucose metabolism and interact with antidiabetic regimens. Confirm at prescribing.

Compounding legality

Not approved by FDA as of June 2026. NDA under FDA review. Survodutide is not eligible for compounding under 503A or 503B; compounding of unapproved drug substances requires FDA authorization not currently in place for this agent.

Sources

Survodutide is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).